Coronaviridae (e.g., Neonatal Calf Diarrhea Virus, Feline Infectious Peritonitis Virus, Canine Coronavirus, Etc.) Patents (Class 424/221.1)
  • Patent number: 6241989
    Abstract: The present invention relates to multivalent recombinant raccoon poxviruses, containing more than one exogenous gene inserted into either the thymidine kinase gene, the hemagglutinin gene, or a combination thereof. Disclosed is the use of the multivalent recombinant raccoon poxviruses as vaccines to immunize felines against subsequent challenge by feline pathogens. Also disclosed is a method of making a a multivalent recombinant raccoon poxvirus by a recombination process involving the construction of an insertion vector into which the exogenous genes are inserted, and flanking the inserted genes are sequences which can recombine into the raccoon poxvirus thymidine kinase gene, or the hemagglutinin gene, or a combination thereof; introducing both the insertion vector containing the exogenous genes, and raccoon poxvirus into susceptible host cells; and selecting the recombinant raccoon poxvirus from the resultant plaques.
    Type: Grant
    Filed: November 3, 1995
    Date of Patent: June 5, 2001
    Assignees: Cornell Research Foundation, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Fred W. Scott, Christopher K. Ngichabe, Liangbiao Hu, Joseph J. Esposito
  • Patent number: 6168787
    Abstract: The present invention is directed to compositions and methods for the induction of immune responses in mammals against enveloped animal viruses. More particularly, the invention provides vaccine compositions containing multiple MHC allotypes. By generating an immune response against these MHC molecules, virus or virus-infected cells expressing foreign MHC molecules can be attacked prior to infection of cells in the immunized host. In some embodiments, the vaccine compositions contain viral antigens and adjuvants as well. The vaccine compositions may comprise intact cells, cell-derived membrane preparations or recombinantly or chemically produced MHC molecules or fragments thereof.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: January 2, 2001
    Assignee: John Wayne Cancer Institute
    Inventor: Donald L. Morton